The Italian biotech firm is working on implantable leads for neuromonitoring and brain-machine connections. Now, the company announced that it has raised €15M in its Series C. One of the investors is the Italian single family office of the Rossi Luciani family.WISE: Medical device company working on implantable leadsWISE is a biotech company based in Milan and Berlin working on implantable Neuromodulation and Neuromonitoring leads. Through WISE’s WCS electrode, intraoperative neuromonitoring is enabled. The now-raised funds are used to develop a novel product the SCS EXPERT. Through SCS, a implantable multi-column paddle lead, Spinal Cord Stimulation (SCS) gets possible. Thereby, chronic pain can be treated. More than 328 million people suffer from chronic pain globally. WISE’s approach offers a treatment way apart from the usually prescribed drugs.$15M Series C Financing
Round: Italian Rossi Luciani Single Family Office (New Frontiers srl) as investorMany new and existing investors participated in WISE’s recent funding round. New investors include CDP Venture Capital, Indaco Ventures as well as EUREKA! Venture. Also, the European Commision granted the company €2.3M earlier this year. Amongst the existing investors is New Frontier srl, which is an investment vehicle of the Rossi Luciani family office. New Frontier is focused on startups, especially in the biotech sphere. The Rossi Luciani family is the majority shareholder of listed electrical device company Carel Industries SpA.
Source: Picture source: Relevant family office articlesYou also might like researchgermany.com’s .Relevant family office lists Rated 4.00 out of 5 €399,99 including VAT Rated 4.67 out of 5 €499,99 including VAT Rated 4.67 out of 5 €1.499,99 including VAT
User Comments1. Williams,
Lucas: Comment sample 1...2. Owen
Morgan: Comment sample 2...3. Turner,
Charlotte: Comment sample 3...4. Daniel W.: Comment sample 4...5. Evans,
Hannah: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.
(Editors: admin)
Disclaimer & Copyright Notice:
This article is edited and compiled by the editorial team at WealthShield Asia based on publicly available information. It is intended for informational purposes only and does not constitute legal, financial, or investment advice.
We respect intellectual property rights. If you believe that any part of this article infringes upon your copyright or other legal rights, please contact us at
admin@wealthshield.asia. We will promptly review and remove the content if necessary.
All rights reserved. Unauthorized reproduction or redistribution is prohibited.
